Abstract: Several prognostic factors are evaluated in the breast carcinoma and there is a need for new markers for better discrimination of the biologic differences in the primary tumor. Epidermal growth factor (EGF) is presumed to play an important role in the local regulation of breast cell proliferation so, the aim of the current study, was to evaluate the serum level of EGF in breast cancer female patients in comparison with other prognostic parameters. It was carried out on fifty-seven females divided into two groups. A control group of twenty healthy women of comparable age and socioeconomic status with a group of thirty-seven breast cancer patients. All females were chosen non-pregnant, not on contraceptive therapy, not previously exposed to radiation, and have no previous history of cancer. To all patients, thorough clinical examination, plain X-ray for the chest and ultrasonography of the abdomen and pelvis were done. Preoperative fine needle aspiration cytology was also done for their breast lumps. In addition, blood samples were collected and analyzed for hemoglobin, fasting serum glucose, urea, and creatinine levels, aspartate and alanine aminotransferase activities, and also the epidermal growth factor level. The breast cancer tissues, removed by surgery, were subjected to histopathologic examination. The median of serum EGF in breast cancer patients group was relatively lower than that in control group but it did not reach the level of significance. No significant differences between the serum EGF levels were found in relation to the change in tumor size, type, grade, and stage. However, there was positive correlations between EGF level and tumor size (r=0.341, p=0.039) and AJCC stages (r=0.354, p=0.032). Also, in patients without lymph node metastasis, there were positive correlations between serum EGF level and both tumor size (r=0.596, p=0.024) and AJCC stages (r=0.596, p=0.024). In patients having lymph node metastasis, there was significant negative correlation between serum EGF level and the number of lymph node metastasis (r=-0.859, p<0.001).There was significant increase in EGF level in patients having lymph node metastasis ( 3 LN) when compared to patients having no LN metastasis (p=0.004) and its level in patients having ( >3 LN) metastasis was significantly decreased than that in both patients having no LN metastasis (p=0.019) and patients having 3 LN metastasis (p<0.001). In addition, EGF level was significantly increased in patients with estrogen receptor (ER) negative than in patients with ER positive (p=0.049). Also, there was a negative correlation between EGF level and ER positivity (r=-0.454, p=0.005). Similar correlation was also found in patients having LN metastasis (r=-0.680, p<0.001). But there was no significant relationship between serum EGF level and the state of progesterone receptor. In conclusion, determination of serum EGF in combination with certain histological parameters could be useful in determining tumor prognosis and in deciding the selection of treatment modality, however, more better results could be obtained on adding the determination of Epidermal growth factor receptor (EGRF) level in resected tumors.
INTRODUCTION
The control of proliferation of human breast carcinoma is known to involve complex interactions between hormones and growth factors, e.g, prolactin, insulin, IGF-1, EGF, and basic fibroblast growth factor . (3, 4) It has been found that IGF-1 and EGF appeared to stimulate human breast stromal cell growth in a synergistic manner . (5) Of these, EGF is the most important . (6) The EGF is a single polypeptide chain having asparagine at NH2-terminus, arginine at COOH-terminus, and a total of 53 amino acid residues, (6 KDa) with three internal disulfide linkages. The EGF can be detected in many tissues and nearly all body fluids but high levels of EGF exist in saliva, urine, gastric juice, milk, breast cyst fluid, and also in amniotic fluid . (10) (11) (12) As a mitogen, EGF binds, with high affinity, to specific cell surface receptors The extent of lymph node metastasis remains the most reliable indicator for staging and progression of cancer breast. (15) However, it was suggested that in patients with lymph node metastasis, the growth of breast carcinoma was related to an accelerated EGF-dependent of cell division . (16) This work aimed at estimation of serum levels of EGF in females with breast carcinoma and correlation between its level with the well known prognostic parameters, e.g., tumor size, grade, stage, number of lymph nodes involved, and the presence or absence of estrogen and progesterone receptors.
MATERIAL AND METHODS
Fifty-seven adult females were included after taking their consents. They were divided into two groups: To all females, the following were done: thorough clinical examination, plain X-ray for the chest, and ultrasonography of the abdomen and pelvis.
For the patients group, pre-operative fine needle aspiration cytology was done for the breast lumps and only those who were diagnosed as breast carcinoma were included in the study.
Following twelve hours fasting, venous blood ( 6 ml) was withdrawn from each subject, allowed to clot and serum was separated. Screening laboratory tests were performed and an aliquot was immediately transferred to an
Eppendorf tube for each studied subject for estimation of serum EGF. They were stored at -20°C until analysis.
Screening laboratory investigations including estimation of fasting serum glucose , (17) serum creatinine (17) and uric acid (18) levels were done as well as determination of alanine (19) and aspartate (17) aminotransferase activities. Also estimation of serum EGF by ELISA (17, 20) (Table 4c ).
In addition, EGF level was significantly higher in breast cancer patients with ER negative patients than that in ER positive patients (Table 4e) . Also, EGF level was significantly higher in breast cancer patients having ER-ve and PR +ve than in patients having both +ve ER and PR (Table 4g ). The state of PR also did not change the level of EGF (Table 4f ).
( kDa, heat-and acid-stable polypeptide which stimulates proliferation of many normal and malignant cells. (14, 21) To perform its function, EGF binds with high affinity to specific low capacity receptors (EGFRs ). (22) Within normal cells, the EGFR is tightly regulated . (23) Increased EGF expression has been associated with poor clinical outcome in many malignancies
. (24) Epidermal growth factor in blood of humans is found in both platlets and plasma (25) . Circulating EGF is a pool from different secretory tissues . (20) It is among the peptide growth factors active in breast glandular tumor cell proliferation and it plays a major role in breast tumor development . (26) In the present study, estimation of the serum level of EGF in thirty-seven females with breast carcinoma ranged from 5.5 to 303 pg/ ml with a median of 42.5 pg/ ml, showing a relative decrease than that in controls although insignificant (Table 3) . This is because EGF is produced and acts locally so its concentrations in serum or urine are not necessarily relevant . (27) It was reported that tumor-associated macrophages are able to promote tumor growth directly by secreting breast tumor mitogens such as EGF (28) , also there is increase in its EGF has a role in the development of fibrocystic changes in the breast, its high level is a strong prediction of breast cancer risk. It directs cell migration and invasion and it is also important for breast cancer progression . (10, (31) (32) (33) Lymph node metastasis in breast cancer, is the most important prognostic factor, its number has an inverse correlation with survival . (34) On dividing the whole breast cancer females, in present study, according to the presence (23 cases) or absence of lymph node metastasis (14 cases), the serum EGF in both subgroups of patients without and with lymph node metastasis showed no significant difference from control group (Table 3) . While, the serum EGF level in patients having metastasis in less than or equal to three LN (n = 13 cases, 35.1% of whole patients) (Table   4c ), showed a significant increase than its level in node negative patients. Since (Table 4c ).
In addition, in the patients having breast cancer with LN metastasis, EGF showed significant negative correlation with the number of LN metastasis (r=-0.859, P=0.000), (Table 5 ) and ( Figure 6 ).
This goes in agreement with the work of Bolufer et al. (1993) . (35) Tumor size is an important prognostic factor in breast cancer patients having an inverse correlation with survival . (34) In the present study, although there was a trend for the median of EGF concentration to increase with increase in tumor size, but this trend did not reach the level of statistical significance (Table   4a ). This finding is in accordance with other studies . (35, 36) In growth. (31) There are certain morphological types of breast cancer which have a distinct favourable clinical course. In the present study, infiltrating ductal carcinoma was the predominant type (70.3%) (Table 1c ).
There was no statistically significant relationship between EGF levels and tumor type. This finding is in the accordance with another previous study . (36) The grading of breast tumor is another important prognostic factor including nuclear characteristics and degree of differentiation. (34) In the present study, most patients (81.8%) had tumors with grade II. (Table 1d ). Since the number of patients with grade I and grade III breast carcinoma is too small, there was no significant difference in the serum EGF levels in relation to tumor grading (Table 4b ). This finding was in accordance with other studies . (33, 35, 36) The American Joint Committee on Cancer (AJCC) published in 2006, a breast cancer staging system based on the TNM classification. (37, 38) concentrations were positive and lower concentrations were negative prognostic factors for disease free survival. (40, 41) In the present study, serum EGF level in patients having ER-ve showed a significant increase than that in patients having ER+ve (Table 4e ). In addition, in the whole patients group, serum EGF levels showed significant negative correlation with ER positivity (r=-0.454, P=0.005) ( Table 5 ) and (Figure 3 ).
Similar results were also reported. (14, 35, 42) It was reported the fact that the magnitude of EGF binding on tumors was independent of either estrogen or progesterone receptor. The highest quantities of EGF binding were expressed on tumors lacking steroid receptors. (43) Epidermal GF receptor positive tumors are hormone unresponsive and more aggressive than EGF receptor negative tumors (13, 14, 44) It was proposed that EGF is the driving force for the autonomous growth of ER negative breast cancer cell via the EGF -EGFER -initiated signal transduction pathway . (45) In the present study, serum EGF level showed no significant difference in patients with progesterone receptors positive (PR+ve) and (PR-ve) tumors (Table 4f ). The findings are in accordance with other studies. (35, 36) However, another study suggests that progesterone and EGF may play opposing roles in metastasis . (46) On combining the state of ER and PR in the present study, the serum level of EGF showed a significantly higher level in patients with ER-ve but PR+ve tumors than that in those with both ER and PR+ve tumors (Table 4g) increases the over expression of EGF that occurs in malignancy. (20) In addition, since EGF stimulates the synthesis of its own receptor, it was suggested that EGF is a major growth-stimulating factor for ER-ve cells through the effect of EGFR. (45) In conclusion, determination of serum EGF level in combination with the known prognostic parameters is useful in determining the tumor prognosis and more beneficial results could be attained if its determination is combined with the determination of EGFR on tumor tissue.
RECOMMENDATION
Further studies are necessary in order to assess the possible clinical value of EGFR.
